Monthly Archives: November 2015

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD treated the first prostate cancer patient in California with minimally invasive HIFU on November 18, in San Francisco at the San Francisco Surgery Center (SFSC). This will be the second patient ever treated in the country using Sonablate HIFU technology. HIFU Prostate Services has partnered with Lazar and SFSC to establish a HIFU Center of Excellence where patients can receive the recently FDA-cleared Sonablate HIFU treatment. SFSC is located in [...]

2017-12-13T13:37:54+00:00 November 18th, 2015|

Recently FDA approved HIFU for Prostate Cancer makes news in Kentucky

HIFU is making news all over the United States now that it has achieved FDA approval. In the news video below HIFU Prostate Services physician partner, Dr. John Jurige speaks with Louisville's news station, WHAS about HIFU for prostate cancer. Dr. Jurige treated the first patients in the US with HIFU outside of a clinical trial on November 10, 2015. View the video below ... HIFU Prostate Services has partnered with Dr. Michael Lazar and San Francisco Surgery Center to establish a HIFU Center of Excellence in downtown San Franciso where patients can now receive the Sonablate HIFU treatment. Dr. Lazar also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored [...]

2017-12-13T13:37:54+00:00 November 18th, 2015|

Minimally Invasive Prostate Cancer Treatment HIFU Now Available in the U.S.

After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation. HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around [...]

2017-12-13T13:37:55+00:00 November 12th, 2015|

HIFU Prostate Services Names Michael J. Lazar, MD Medical Director

Nov. 4, 2015 -- HIFU Prostate Services (HPS) has named Dr. Michael Lazar as HPS Medical Director. As HPS Medical Director Dr. Lazar will provide medical guidance and proctoring to new physicians that are being trained on the Sonablate® HIFU system in surgery centers around the country. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation. Lazar has been treating with HIFU since 2007 and is one of three US physicians who worked with SonaCare Medical, LLC to supervise HIFU treatments during FDA clinical trials. Dr. Lazar will operate his own HIFU Program, in partnership with HPS, offering prostate treatments in downtown San Francisco, [...]

2017-12-13T13:37:55+00:00 November 11th, 2015|

HIFU Now Available In the U.S. Ending a Long Awaited FDA Approval Process

After much anticipation the FDA has finally approved for market in the United States the Sonablate® for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence which are typically reported with surgery and radiation. HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Newly appointed HPS Medical Director Michael J. Lazar, MD is set to provide medical guidance and proctoring to new physicians who will now be trained on the Sonacare® HIFU system in surgery centers around [...]

2017-12-13T13:37:55+00:00 November 10th, 2015|